• Zoledronic Acid: Cancer Assay Workflows

  2026-09-11

  Build reproducible Zoledronic Acid workflows for cancer cell apoptosis, breast cancer models, multiple myeloma treatment research, and osteolytic bone disease prevention. This guide emphasizes formulation control, orthogonal readouts, and cautious translation of mechanistic methods from a recent immune-metabolism study.

• AO/PI Staining Solution for Mechanistic Cell Assays

  2026-09-11

  Discover how AO/PI Staining Solution improves fluorescence-based cell counting in inflammation and apoptosis research. This guide connects membrane-integrity measurements with the mechanistic findings of a diabetic nephropathy study while defining practical assay decisions and limitations.

• Baicalein: 12-LOX Research Guide

  2026-09-10

  Baicalein, also called 5,6,7-trihydroxy-2-phenylchromen-4-one, is a flavonoid research compound used to study 12-lipoxygenase, arachidonic acid metabolism, apoptosis, inflammation, and cancer-cell biology. Product data describe a 270.24 g/mol solid with limited water solubility and high solubility in DMSO, while current neurotoxicity evidence supports formononetin rather than baicalein.

• AI-10-49: A Causal Probe for inv(16) AML

  2026-09-10

  AI-10-49, a selective CBFβ-SMMHC inhibitor, enables layered analysis of fusion-protein dependency in inv(16) acute myeloid leukemia. This guide connects target engagement, RUNX1 chromatin recovery, and the N-MYC/eIF4G1 survival program to practical assay design.

• Sodium Salicylate as an NF-κB Inhibitor

  2026-09-09

  Sodium salicylate is a research reagent described as an NF-κB inhibitor with applications in inflammation, immunology, oxidative stress, and cell signaling studies. The B2028 product specification reports high purity, broad solvent compatibility, and storage at −20 °C, while current pancreatic cancer nanomedicine evidence supports a separate stromal-remodeling strategy rather than a demonstrated sodium salicylate therapy.

• Cabozantinib (XL184) for Adaptive Cancer Signaling

  2026-09-09

  Cabozantinib and XL184 support more than endpoint viability assays: they enable coordinated studies of RTK signaling, angiogenesis, phosphoproteomic adaptation, and tumor-cell motility. This workflow translates acute-versus-chronic exposure findings into practical assay choices for renal cell carcinoma, medullary thyroid cancer, and endothelial models.

• β-Elemene in Adipogenesis and Metabolic Assays

  2026-09-08

  β-Elemene is a practical tool for separating lipid remodeling from nonspecific toxicity in 3T3-L1 adipogenesis and insulin-resistance experiments. This workflow connects AMPK-centered metabolic readouts with carefully controlled apoptosis, inflammation, neuroprotection, and analytical applications.

• PF-573228 FAK Inhibitor Workflow Guide

  2026-09-08

  Use PF-573228 to test how focal adhesion kinase connects matrix mechanics with dentinogenesis, cancer-cell behavior, and endothelial responses. This practical guide combines stiffness-aware controls, target-engagement assays, dosing guidance, and troubleshooting for more interpretable results.

• BFH772 (VEGFR2 inhibitor): Protocol Guide

  2026-09-07

  BFH772 is a selective small-molecule VEGFR2 inhibitor for controlled studies of VEGFR2-mediated angiogenesis and tumor-model signaling. Its organic-solvent compatibility and water insolubility make it unsuitable for workflows requiring aqueous delivery or broad-spectrum kinase inhibition without additional formulation and selectivity controls.

• PF-573228: FAK Inhibition Beyond Stiffness

  2026-09-07

  PF-573228 is a potent FAK inhibitor for dissecting how adhesion signaling connects matrix mechanics with differentiation, cancer-cell behavior, and angiogenesis. This article translates the LAMB1–FAK–MEK1/2 dentinogenesis findings into a causal, multi-endpoint assay strategy while defining key interpretation limits.

• PX-478 2HCl: HIF-1α Workflow Guide

  2026-09-05

  PX-478 2HCl provides a titratable way to interrogate HIF-1α in normoxic and hypoxic cancer models, including radiosensitization studies and tumor-ischemia research. This guide translates its product specifications and a recent macrophage-metabolism study into practical assay design, controls, and troubleshooting decisions.

• Omeprazole (A2845): Workflow and QC Guide

  2026-09-04

  Omeprazole (A2845) is a research-grade H+,K+-ATPase inhibitor for controlled studies of gastric acid secretion, proton pump inhibition, and antiulcer mechanisms. This guide covers solvent selection, assay controls, storage, and troubleshooting; the compound is not intended for diagnostic, clinical, or therapeutic use.

• Enzalutamide, ARv7, and TNBC Metastasis

  2026-09-04

  This 2025 study connects androgen receptor variant 7 (ARv7) localization with poor outcomes in triple-negative breast cancer (TNBC) and examines how Enzalutamide and EPI-001 affect metastatic and epithelial-to-mesenchymal transition markers. Its combination of patient immunohistochemistry, TCGA-BRCA analysis, and MDA-MB-231 functional assays provides a mechanistic framework for studying androgen receptor-mediated pathway modulation beyond prostate cancer.

• DMXAA: A Mechanism-First Vascular Biology Guide

  2026-09-03

  DMXAA (Vadimezan) is more than a vascular disrupting agent: it is a useful mechanistic probe for separating endothelial collapse, VEGFR2 signaling, and tumor-cell apoptosis. This guide presents an assay-centered framework for cancer biology research and interprets a recent trafficking study without overstating pathway evidence.

• RapaLink-1: Third-Generation mTOR Inhibitor Workflows

  2026-09-03

  RapaLink-1 combines mutation-aware mTOR kinase targeting with practical workflows for glioma growth assays, cell-cycle profiling, and exploratory dormancy studies. Its strongest differentiation is a bivalent mechanism, but embryonic applications require careful validation because the reference protocol did not directly test RapaLink-1.

8701 records 1/581 page Next 12345 下5页 Last page